Recent Advances in the Pursuit of an Effective Acinetobacter baumannii Vaccine

Patrick S. Gellings 1, Ashley A. Wilkins 1,2, and Lisa A. Morici 1,*

1 Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA; pgellings@tulane.edu (P.S.G.); awilk3@lsuhsc.edu (A.A.W.)
2 Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA
* Correspondence: lmorici@tulane.edu; Tel.: +1-504-988-1113

Received: 30 October 2020; Accepted: 17 December 2020; Published: 19 December 2020

Abstract: Acinetobacter baumannii has been a major cause of nosocomial infections for decades. The absence of an available vaccine coupled with emerging multidrug resistance has prevented the medical community from effectively controlling this human pathogen. Furthermore, the ongoing pandemic caused by SARS-CoV-2 has increased the risk of hospitalized patients developing ventilator-associated pneumonia caused by bacterial opportunists including A. baumannii. The shortage of antibiotics in the development pipeline prompted the World Health Organization to designate A. baumannii a top priority for the development of new medical countermeasures, such as a vaccine. There are a number of important considerations associated with the development of an A. baumannii vaccine, including strain characteristics, diverse disease manifestations, and target population. In the past decade, research efforts have revealed a number of promising new immunization strategies that could culminate in a safe and protective vaccine against A. baumannii. In this review, we highlight the recent progress in the development of A. baumannii vaccines, discuss potential challenges, and propose future directions to achieve an effective intervention against this human pathogen.

Keywords: Acinetobacter baumannii; antimicrobial resistance; SARS-CoV-2; outer membrane vesicles; live-attenuated vaccine; subunit vaccine

1. Introduction to A. baumannii

Acinetobacter are non-motile Gram-negative coccobacilli that are found ubiquitously in nature, but are predominantly found in soil, water, and sewage [1]. There are over 50 different species of Acinetobacter, most of which are non-pathogenic [2]. Of the few pathogenic species, a cluster of phylogenetically related species, known as the A. calcoaceticus-baumannii (ACB) complex, cause the majority of infections [3]. Because A. baumannii is considered the most prominent and virulent, infections caused by the ACB complex are often simply referred to as A. baumannii infections [3]. A. baumannii is predominately a nosocomial, opportunistic pathogen that has the potential to cause severe disease and death. For decades, the medical community has observed A. baumannii develop new mechanisms to resist antimicrobial treatments, leading to fewer clinically-effective therapeutics. Because of its extensive multidrug resistance, development of prophylactic vaccines to protect at-risk populations has received considerable investigation with several promising vaccine platforms reported in pre-clinical studies during the last decade. In this review, we will briefly summarize the disease manifestations, transmission, and antimicrobial resistance mechanisms of A. baumannii, followed by an in-depth review of the aforementioned vaccine studies.
1.1. Disease Manifestations

*A. baumannii* is primarily considered an opportunistic pathogen that most commonly affects hospitalized patients, immunocompromised individuals, and military personnel with battlefield wounds [4–9], especially in humid climates [10]. *A. baumannii* infections are associated with organs and organ systems that have a high fluid exchange rate such as the urinary tract, respiratory tract, and peritoneal system [11]. The bacteria will most commonly cause pneumonia, sepsis, skin and soft tissue infections, and meningitis [11]. It has been estimated that *A. baumannii* is responsible for nearly 12% of all hospital-acquired infections worldwide, but rates for individual countries can be as low as 1–2% in some northern European countries and as high as one third of all cases in Asian countries [12–15].

Hospital-acquired pneumonia is one of the most common clinical manifestations of *A. baumannii* infections and occur most commonly in patients receiving mechanical ventilation in an intensive care setting [6,15–18]. These pneumonia cases can be difficult to treat, especially because of the prevalence of antibiotic resistance. A recent meta-analysis of 126 studies encompassing 29 countries determined that multidrug-resistant *A. baumannii* was present in 80% of all hospital-acquired and ventilator-associated pneumonia cases worldwide [19]. Serious Covid-19 cases result in hospitalizations and patients requiring mechanical ventilation. A number of retrospective studies have identified a noteworthy percent of Covid-19 patients suffering from co-infections either before or after developing Covid-19 symptoms and hospital admission. The most common culturable bacterial pathogens in Covid-19 patients appear to be *Klebsiella pneumonia* [20–22], *Legionella pneumophilia* [21–23], *Enterobacter cloacae* [24], *Staphylococcus aureus* [22,25], *Streptococcus pneumoniae* [25], and *A. baumannii* [20–22,24–28].

Sepsis is another serious complication associated with *A. baumannii* infections [29–31]. For every hour treatment is delayed, septic patients infected with *A. baumannii* have a 5–10% increase in mortality [31]. Sepsis cases caused by *Acinetobacter* species accounted for the third highest crude mortality rates in ICUs, with mortality rates exceeding 50% in some studies and were only surpassed by *Pseudomonas aeruginosa* and *Candida* species infections [32]. A retrospective cohort study determined that approximately 1% of all sepsis cases analyzed from a hospital had a blood culture that was positive for *A. baumannii* [29]. Of those cases, 82.3% of cultures were considered multi-drug resistant and 16.8% were extensively drug resistant [29,30].

Bacteria are the main cause of the 14 million outpatient and 850,000 inpatient skin and soft-tissue infections (SSTIs) each year [33]. Members of the ESKAPE (Enterococcus faecium, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) family make up the bulk of SSTIs, with *A. baumannii* a leading cause of SSTIs that occur within a military environment [4,31,34]. Over the last 10–15 years, the U.S. military has recorded a significant increase in MDR *A. baumannii* infections with up to 83% of SSTIs caused by *A. baumannii* associated with combat zone operations [4,31]. Multidrug-resistant (MDR) *A. baumannii* infections are present in both trauma and burn victims as these injuries often result in secondary infections [31].

Finally, meningitis is another serious complication of *A. baumannii* infections. Nosocomial cases of *A. baumannii* meningitis are often caused by head trauma, leaking cerebrospinal fluid, or external ventricular drainage [35–37]. Mortality rates of nosocomial meningitis caused by *Acinetobacter* species can reach 40% in developed countries and up to 70% in developing countries [38].

1.2. Transmission

*A. baumannii* can be spread via aerosol droplets, person-to-person contact through sloughing of skin, sputum, urine, or feces, or through contact with a fomite [39–43]. Fomite spread is particularly problematic in a hospital setting. A study that observed over 250 patient interactions discovered culturable *A. baumannii* on the hands or gloves of healthcare workers in 30.3% of interactions [44]. Further, both antibiotic-resistant and antibiotic-susceptible *A. baumannii* strains are easily transferred from examination gloves made of nitrile to polypropylene plastic surfaces where the bacteria can be transferred to another healthcare worker or to a patient [45]. A separate study found
carbapenem-resistant *Acinetobacter baumannii* (CRAB) present in the sputum of ventilator patients suggesting that, despite the closed nature of a ventilation system, the bacteria could still be readily spread in droplets emitted by CRAB patients [40].

The ease of *A. baumannii* spread is largely due to three separate traits: resistance to desiccation, the ability to form biofilms on abiotic surfaces, and aptitude for adhering to host cells. In fact, *A. baumannii* has been found to be viable after 2 months on an abiotic surface in a controlled laboratory setting, but endemic strains are believed to be able to survive for up to three years in inhospitable environments [46,47]. The ability of *A. baumannii* to survive for long periods of time without hydration is largely attributed to its outer polysaccharide capsule [48–51] and its ability to form biofilms to resist desiccation [52–55]. The thick polysaccharide capsule enables the bacteria to develop biofilms which retain moisture and persist for long periods of time [51]. The *A. baumannii* capsule is produced from a rich diversity of capsule loci, with over 100 distinct capsule types identified to date. The capsules can contain unique glycans with atypical acetylation sites or may be exclusively decorated with aminosugars [56,57]. The presence of RecA, a main player in homologous recombination and SOS mutagenesis, also contributes to the ability of *A. baumannii* to survive desiccation [58]. Bacterial DNA is routinely damaged during desiccation and RecA is known to repair DNA during rehydration and to confer selective advantages to the bacteria [58]. It was previously shown that a single round of desiccation and rehydration, or heat-shock of *A. baumannii* resulted in a 50-fold increase in the number of genomic mutations which was dependent on the presence of RecA [58].

### 1.3. Antimicrobial Resistance

Antimicrobial resistance (AMR) among bacteria has become a global crisis due to innate or acquired resistance mechanisms and has caused an estimated two million illnesses and 23,000 deaths to date [59]. By 2050, at least 10 million individuals are expected to die from multidrug-resistant organisms unless the medical and scientific communities make a substantial investment in research focused on understanding antibiotic resistance and developing new or alternative therapies [59]. While AMR is quickly becoming an issue for many bacteria, it is especially dire for *A. baumannii*. The CDC recently reclassified CRAB from its previous status of Hazard Level Serious to Hazard Level Urgent, meaning that the level of antibiotic resistance requires aggressive action and poses a notable threat to public health [59]. According to the CDC, CRAB alone has resulted in $281 million dollars in healthcare costs and contributed to an estimated 8,500 hospitalizations and 700 deaths in the US in 2017 [59]. In the absence of new medical interventions, the number of cases will certainly continue to grow.

During its initial discovery approximately half a century ago, all *A. baumannii* isolates were characterized as being a member of either global clone 1 (GC1) or global clone 2 (GC2) families [60–62]. These clonal groups were initially known to only possess genes that conferred resistance to tetracycline, sulfonamides, and aminoglycosides but eventually went on to develop resistance to carbapenems, fluoroquinolones, and some third generation cephalosporins, but how and when these resistance traits developed varied between clonal groups. Eventually, there was considerable genetic variation in the genes responsible for the structures of *A. baumannii* lipooligosaccharide (LOS) and capsule, allowing researchers to genetically distinguish between clonal groups and to determine antibiotic resistance [60,63–65]. For example, there are a group of GC1 *A. baumannii* strains that became resistant to third generation cephalosporins through the insertion of Tn6168, a ISAba1-bounded transposon that contains a second copy of an *ampC* gene [66]. In addition, another GC1 clade possess a OCL3 variant that alters the structure of LOS compared to other strains that possess the OCL1 variant which conferred carbapenem resistance [63,65]. These variants, along with many others, highlight the extraordinary clonality associated with *A. baumannii* isolates.

*A. baumannii*’s remarkable ability to develop resistance to numerous classes of antibiotics occurs through multiple mechanisms, including the acquisition of mutations in antibiotic targets; modification of the antibiotic itself; decreased outer membrane permeability to limit the entrance...
of antibiotics, and multi-drug efflux pumps. For example, *A. baumannii* contains an abundance of membrane transporters from the resistance-nodulation-cell superfamily. These transporters are known to contribute to chloramphenicol, macrolide, trimethoprim, fluoroquinolone, aminoglycoside, and β-lactam resistance [67,68]. In addition, numerous reports have documented *A. baumannii* clinical strains with resistance to colistin, an antibiotic typically used as a last resort treatment [69]. This is particularly concerning as the rate of new antibiotics entering the market has steeply declined over the past several decades. This drop off is largely due to an increase in costs necessary to navigate regulatory agency approval processes; the relatively short lifespan of an antibiotic due to rapid development of antibiotic resistance; and the high profit margins associated with pharmaceutical companies switching to developing and manufacturing drugs used for chronic conditions including cancer, heart disease, and persistent viral infections such as HIV and Hepatitis [70].

While select antibiotics retain some effectiveness against *A. baumannii*, including the cephalosporin Cefiderocol and newer tetracyclines like Eravacycline and TP-6076, there is a real threat that emerging antimicrobial resistance will eventually render these novel antibiotics useless [71]. This uphill battle against *A. baumannii* stresses the importance of shifting the medical community’s focus from therapeutics to strategies that can prevent infections in the first place.

2. **Vaccine Candidates for *A. baumannii***

Vaccination represent a promising and plausible strategy for preventing *A. baumannii* infections. Moreover, the large degree of clonality observed among *A. baumannii* clinical isolates may result in broad vaccine coverage if conserved antigens are targeted. In this regard, a multitude of vaccine candidates have been explored for *A. baumannii* over many decades with varying degrees of success. In the past decade, a number of multivalent vaccines including live attenuated strains, bacterial ghosts, outer membrane vesicles/complexes, and DNA or subunit vaccines have been explored with promising outcomes (Table 1). In this review, we will examine each of these platforms and summarize the immunogenicity and protective efficacy observed in rodent models. To our knowledge, none of the candidates discussed in this review have advanced beyond pre-clinical evaluation.

2.1. **Live-Attenuated Strains**

Live-attenuated vaccines are composed of bacteria that have been altered to reduce or eliminate pathogenicity, allowing the immune system to encounter the pathogen without the risk of disease. The main benefit of using live-attenuated strains for vaccination is that the mutant strain presents multiple antigens that mirror many of those presented by fully virulent strains, producing both antibody and cellular immune responses to multiple targets [72]. The drawbacks of live attenuated vaccines is the possibility of reversion to virulence, either through horizontal gene transfer or spontaneous mutations [72]. It is also unclear if live attenuated vaccines would be approved for use in immunocompromised populations, such as those at greatest risk for *A. baumannii* infection. Few vaccine studies utilizing live attenuated strains of *A. baumannii* have been performed in recent years, but a D-glutamate strain of *A. baumannii* was recently created and evaluated as a live attenuated vaccine [73]. The mutations introduced in the *murI1* and *murI2* genes created a strain of *A. baumannii* that was less virulent in BALB/c mice but still generated both antibody- and cell-mediated immunity and conferred increased survival to immunized animals after challenge with multiple, pathogenic strains of *A. baumannii* [73]. A similar study examined the protection elicited by a thioredoxin-deficient *A. baumannii* strain (*ΔtrxA*) [74]. Thioredoxins are crucial for bacteria to counter oxidative stresses and redox regulations. Vaccination with the *ΔtrxA* strain led to full protection against infection with a clinical *A. baumannii* isolate [74,75].

2.2. **Bacterial Ghosts**

Bacterial ghosts (BG) begin as live bacteria but are processed to remove all cytosolic components to leave behind only the outer membrane of the bacteria. The use of BGs present a few inherent advantages
as they are nonliving and therefore incapable of reverting to a pathogenic phenotype [72]. In addition, BGs are self-adjuvanting and can be modified to carry a unique combination of proteins, DNA, drugs or other small molecules, and have been demonstrated to be efficiently taken up by antigen presenting cells in specific tissues [72]. However, because BGs contain the original bacterial outer membrane, there is some risk of excessive inflammation caused by the presence of native LPS [72]. *A. baumannii* BGs (strain Ali190) were used to vaccinate Sprague-Dawley rats orally, subcutaneously, intramuscularly, or intraperitoneally before being challenged with $10^8$ CFU of the homologous *A. baumannii* strain [76]. *A. baumannii* BGs were highly effective at protecting the vaccinated rats via all routes of administration, with the exception of oral vaccination that conferred only 67% survival [76]. While this initial study yielded positive results, it is imperative to test the ability of *A. baumannii* BGs to protect against a variety of *A. baumannii* strains, especially distinct clades to determine if protection is serotype-dependent or independent for BGs.

2.3. Outer Membrane Vesicles or Complexes

Outer membrane vesicles (OMVs) are small, non-infectious particles secreted by Gram-negative bacteria, including *A. baumannii*, that range in size from 10–300 nm in diameter [77]. OMVs are composed of a wide variety of bacterial components, including DNA, RNA, lipo- and polysaccharides, and proteins. As such, OMVs are multivalent in nature and provide multiple antigens that can elicit both antibody and T cell responses against numerous bacterial targets [78]. Previous studies have already validated OMV-based vaccines using a diverse array of bacteria including *Escherichia coli* [79–81], *Bordetella pertussis* [82,83], *Burkholderia pseudomallei* [84–87], and even a commercially available vaccine for *Neisseria meningitidis* serogroup B [88,89].

Multiple studies have evaluated the efficacy of OMV-based *A. baumannii* vaccines. In one study, mice vaccinated in a prime-boost fashion demonstrated increases in overall IgG, IgG1, IgG2, and IgM titers, significantly lower bacterial loads, and a significantly higher survival rate compared to their unvaccinated counterparts [90]. The serum obtained from vaccinated mice recognized many of the proteins predicted to be present in OMVs, including OmpA, CarO, OmpW, and a multitude of other putative outer membrane proteins [90]. In a second study, mice vaccinated with *A. baumannii* OMVs produced anti-*A. baumannii* IgG antibodies and displayed increased sensitivity to levofloxacin in an otherwise resistant *A. baumannii* strain [77]. The exact mechanism behind this observation is unknown, but the authors speculated that the vaccine-induced antibodies may target the porins used to export antibiotics from the bacterial cytoplasm, thus increasing susceptibility to quinolone antibiotics.

A potential concern with any OMV-based vaccine is the role LPS plays in immunogenicity and the potential adverse side effects caused by an abundance of endotoxin. These concerns were addressed, in part, by isolating OMVs from the IB010 *A. baumannii* [91]. The IB010 strain possesses a mutated *lpxD* gene making it incapable of producing LPS [91]. Compared to mice vaccinated with OMVs from the parental ATCC19606 strain, the LPS-negative OMVs elicited a similar IgG1, IgG2a, and IgM responses and mice vaccinated with either OMV type had almost identical bacterial loads [91]. However, the LPS-negative OMVs only protected 75% of the mice challenged with *A. baumannii* compared to complete survival of mice vaccinated with a similar amount of WT OMVs [91]. Mice vaccinated with LPS-negative OMVs were completely protected when the concentration of OMVs used was increased 10-fold per mouse or when combined with exogenous LPS [91]. The same bacterial strain was also used in a study to evaluate protection elicited from outer membrane complexes (OMCs) isolated from LPS- *A. baumannii*. Similar to the LPS-negative OMVs, there was little to no toxicity associated with the LPS-deficient OMCs and mice vaccinated with LPS-deficient OMCs had a 60% survival rate at day 7 of the study compared a 95% survival rate of mice vaccinated with LPS-deficient OMCs supplemented with exogenous LPS [92]. Both groups fared significantly better when compared to the 0% survival of control mice [92]. Results from these studies would suggest that, while the absence of LPS may guard against excessive inflammation, the presence of LPS antigen within an OMV-based vaccine appears to contribute to protection.
Finally, it is well-appreciated that the bacterial culture conditions and OMV purification methods will affect final OMV composition. To evaluate this, three different OMV isolation protocols were compared with surprising results. OMVs harvested from supernatants using a series of ultracentrifugation and filtration steps (sOMVs), OMVs harvested through sonicating bacterial cultures (suOMVs), and OMVs obtained by shearing live bacteria using a high-speed disperator (nOMVs) had appreciably different protein profiles. OmpA was the major protein in all OMVs and each purification method resulted in the presence of LPS [93]. More importantly, however, was the variation in immune responses elicited by each type of OMV. Following vaccination, mice given suOMVs had the highest IgG titers, followed by sOMVs, and nOMVs [93]. Not surprisingly, the survival rates of mice challenged with A. baumannii LAC-4 followed the same trend with 70% of mice given suOMVs surviving while only 60%, 50%, and 20% of sOMV vaccinated, nOMV vaccinated, or naive mice surviving, respectively [93]. Collectively, these studies suggest that Acinetobacter OMV-based vaccines show promise, but more research is warranted in order to identify which OMV components are critical for vaccine protection.

2.4. DNA-Based Vaccines

OmpA has received considerable attention as a vaccine antigen because of its ubiquity across A. baumannii clinical isolates and its numerous roles in infection including antimicrobial resistance, biofilm formation, and adherence to host cells [94]. Recently, OmpA was the subject of a DNA-based vaccine that was evaluated in BALB/c mice [94]. The OmpA gene was inserted into the eukaryotic expression pBudCD4.1 vector and injected intramuscularly into mice in a prime-boost fashion [94]. One month after vaccination, IgM and IgG, and the cytokines IL-2, IL-4, IL-12, and IFN-γ levels were significantly increased in vaccinated mice compared to mice vaccinated with an empty vector control [94]. Mice vaccinated with the OmpA DNA vaccine fared considerably better than their negative control counterparts, with 60% of vaccinated mice surviving compared to 0% of the non-immunized mice after intranasal challenge with a lethal dose of A. baumannii [94].

A second group expanded on the initial OmpA DNA vaccine by incorporating the pal gene into an OmpA DNA-based vaccine [95]. Pal, a lipoprotein found in both the bacterial membrane and peptidoglycan layer, was chosen as a vaccine antigen because of its ubiquity in A. baumannii isolates and high level of immunogenicity during natural infection [95]. Both genes were inserted into the pVAX1 expression plasmid and injected into C57BL/6 mice intramuscularly and eventually challenged with A. baumannii intratracheally [95]. All unvaccinated mice died within 3 days of the infection while 60% of mice vaccinated with the Pal/OmpA DNA vaccine survived the length of the study and had lower bacterial burdens 24 h after infection compared to other groups [95]. While these two studies support the idea of pursing DNA vaccines, additional research may be necessary to improve delivery, potency, and eventual licensure of DNA-based vaccines.

2.5. Purified or Recombinant Subunit Vaccines

Surface or outer membrane antigens of A. baumannii represent plausible targets for vaccine-induced opsonizing or bactericidal antibodies. One of the complicating factors in targeting components of the A. baumannii outer membrane is the presence of a dense polysaccharide capsule that shields most outer membrane antigens from immune recognition [96]. In fact, monoclonal antibodies raised against the A. baumannii K1 capsular polysaccharide were shown to decrease K1-positive strain burdens in mice while having no effect on K1-negative strains, suggesting that immunotherapies using monoclonal antibodies against capsular polysaccharides could be effective against A. baumannii infections if clinicians are able to rapidly identify and target the correct capsule profile [97]. Nonetheless, A. baumannii does utilize effector proteins to interact with the extracellular environment and a portion of each protein may extend through the capsule where it can be recognized by the immune system. Identifying those proteins and, more specifically, the regions of those proteins that extend into the environment can provide novel vaccine targets. This strategy has been employed for a number of
A. baumannii virulence determinants, including BAP (biofilm-associated protein), BAP-like protein 1 (Blp1), OmpA, Omp22, and CSU/Pili.

BAP and Blp1 are distinct proteins that contribute to A. baumannii biofilm formation and adherence to biotic and abiotic surfaces, and both are necessary to establish infection [98,99]. In one study, Blp1-specific antiserum was raised in mice and subsequently shown to neutralize and promote opsonophagocytic killing of A. baumannii pandemic strains (international clonal lineages I (IC I) and II (IC II)) [99]. Mice vaccinated with the C-terminal region of the Blp1 protein had an increased survival rate compared to their unvaccinated counterparts, which suggests immune recognition of the C-terminal region of Blp1 could serve as a starting point for a purified recombinant vaccine against A. baumannii [99]. Similar to the Blp1 study, recombinant BAP was used as a vaccine antigen in mice to induce a robust antibody response [100]. In addition to the antibody response, mice vaccinated with recombinant BAP had decreased bacterial burdens and increased survival compared to controls [100]. These studies serve as proof of concept that immunizing with proteins necessary for A. baumannii pathogenesis, specifically biofilm formation, may constitute a protective vaccine.

Outer membrane proteins (Omps) are generally conserved across A. baumannii isolates and contribute to a multitude of A. baumannii traits that complicate treatment including antibiotic resistance, adherence to host cell, and pathogenesis. Omps are found in high abundance within bacterial outer membranes, often protruding through the polysaccharide capsule, making the Omp family of proteins an appropriate vaccine candidate. This has been the case with Oma87 [101], the N-terminal region of Outer membrane porin F (OprF) [102], Omp22 [103], and OmpA [104–106]. Each of these outer membrane protein-based vaccines elicited a robust IgG response and increased the survival rates of mice compared to the naïve control mice [101–106]. OmpA was combined with the secreted serine protease PKF in an antigen cocktail and evaluated for protection against A. baumannii infection [107]. Individually, PKF- and OmpA-immunized animals displayed a 80% and 75% survival rate, respectively, but when combined, OmpA and PKF protected 85% of the mice vaccinated with the duel-component vaccine [107]. Finally, the outer membrane protein FilF, used by A. baumannii during the course of pilus assembly, is exposed to the extracellular environment and was evaluated as a vaccine candidate. Vaccination with FilF decreased the bacterial load in the lungs by 4 logs compared to the adjuvant only control; reduced pro-inflammatory cytokine levels; and led to a 50% survival rate relative to the 0% survival rate of control mice [108]. Of course, outer membrane proteins are transmembrane proteins composed of hydrophilic and hydrophobic regions that impact native confirmation. These regions complicate the purification process but can be overcome by including a series of hydrophilic amino acids at the N-terminal region to increase solubility in hydrophilic environments [109]. Many strategies have been developed to purify these complex proteins, but the overall complexity and costs associated with Omp-based vaccines may prove to be difficult.

There are other proteins present in the A. baumannii outer membrane outside of the Omp family of proteins, in particular the trimeric autotransporter adhesion (Ata), BamA, NucAb, SmpA, and the components of A. baumannii pili. Ata is part of an autotransporter system unique to A. baumannii that is used for adherence to eukaryotic cells or extracellular matrix proteins and contributes to virulence [110,111]. When tested in a murine model, recombinant Ata vaccine elicited a robust antibody response that prevented bacterial adherence, while simultaneously driving opsonophagocytic and bactericidal activities and inducing protective immunity [112]. These results, coupled with the knowledge that ata is a broadly conserved gene across all Acinetobacter species provides support for pursing Ata as a future A. baumannii vaccine [112]. The outer membrane assembly factor BamA was similarly identified as a potential vaccine candidate through in silico analysis. The highly conserved protein elicited a high antibody titer and protected 80% of vaccinated mice when challenged with a lethal dose of A. baumannii through intranasal challenge [113].

A reverse vaccinology approach identified an outer membrane nuclease designated as NucAb as a potential vaccine target based on its non-homology to host proteins, location within the outer membrane, prevalence among clinical isolates, and the presence of anti-NucAb antibodies in mice challenged with
A. baumannii [114]. Mice vaccinated with recombinant NucAb had suppressed inflammation levels and reduced pro-inflammatory cytokines, with the majority of lung inflammation in vaccinated mice resolved within 24 h compared to unvaccinated mice that still had an abundance of bacteria present with necrotic exudates and robust inflammation [114]. However, only 20% of the vaccinated mice survived compared to 0% survival of control mice [114]. Another reverse vaccinology paper predicted the phospholipase D (PLD) produced by A. baumannii, along with an outer membrane lipoprotein named small protein A (SmpA), could elicit a protective immune response [115]. Mice vaccinated with both SmpA and PLD had the highest survival (66.7%), the lowest levels of pro-inflammatory cytokines, the best histology scores following challenge, and the lowest bacterial loads at 3 days post infection [115].

A common feature of many bacterial pathogens is the presence of pili. A. baumannii utilizes its pili for twitching motility, host cell adherence, and natural competence [116]. Components of pili are exposed to the extracellular environment and can be detected by the immune system. Two pilus A. baumannii proteins, CsuA/B and FimA, are known to be recognized by the host’s immune system during infection and stimulate antibody responses. Vaccination with either protein elicited a robust antibody titer in BALB/c mice and, when used together in a vaccine cocktail, produced a 60% survival rate compared to FimA (50%) or CsuA/B (35%) given alone [117].

Another group of vaccine candidates constitute elements used for nutrient scavenging by A. baumannii. Numerous groups have hypothesized that blocking bacterial acquisition of iron or zinc during infection could limit or prevent disease. ZnuD is a zinc outer membrane receptor that contains four loops that are exposed to the extracellular environment and is necessary for A. baumannii survival in the zinc-depleted environments inside host cells [118]. One study assessed vaccination of mice with recombinant proteins containing one or all ZnuD loops. The loops were attached to the C-lobe of the surface lipoprotein TbpB which served as a scaffold during the purification process [118]. The presence of the TbpB scaffold provided no protection against A. baumannii in the mouse model, but the addition of any one loop led to high antibody titers and 25–50% survival in vaccinated mice. However, 100% of the mice survived an A. baumannii challenge when all four of the ZnuD loops were added to the TbpB scaffold [118]. While the production of such a recombinant protein on a commercial scale could be costly due to the intricacies of protein loop folding, these studies do indicate that specific residues of surface-exposed A. baumannii factors can lead to recombinant vaccines that provide high levels of protection in animal models.

Finally, it has been shown that high levels of homology across bacterial genera can lead to cross-protective vaccines that protect against multiple bacterial genera. As an example, it was shown that vaccination against Mycobacterium tuberculosis using Bacillus Calmette-Guérin can protect against Staphylococcus aureus [119] and that a live recombinant attenuated Salmonella can protect against a Mycobacterium tuberculosis infection [120]. It is less appreciated, however, that homology extends to other animal kingdoms, specifically fungi. A computation modeling study identified a number of similarities between the Candida albicans hyphal wall protein Hyr1p and multiple A. baumannii cell surface proteins including hemagglutinin (FhaB) and OmpA [121]. Vaccination with Hyr1p led to a 50% survival rate compared to mice vaccinated with adjuvant alone, all of which died 10 days post infection [121]. This study highlights the potential for AI and computational models to design vaccines that may provide protection against not only multiple bacterial genera, but across different kingdoms of pathogens.
Table 1. Representative list of *A. baumannii* vaccine studies conducted over the past decade reported in NCBI.

| Immunization | Vaccine Platform | Antigens | Adjuvant(s) | Route | Mouse Strain | Strain | Route | Dose | Survival | Ref |
|--------------|------------------|----------|-------------|-------|--------------|--------|-------|------|----------|-----|
|              | Whole bacteria   | *A. baumannii* Δmurl1 or Δmurl2 | - | IP | BALB/c | ATCC 17978 | IP | 3 × 10^8 CFU | 100% | [73] |
|              |                  | *A. baumannii* ΔtrxA | - | IP, SC | C57BL/6 | Clinical Isolate 79 (CD79) | IP | 10^9–10^7 CFU | IP—100% | SC—90% | [74] |
|              | *A. baumannii* (Alu190) BGs | Freund’s adjuvant | Oral, SC, IM, IP, SCA, IMA | Sprague-Dawley rats (male) | Ab190 | IP | 10^8 CFU | Oral—67% | SC, IM, IP, SCA, IMA—100% | [76] |
|              | Formalin-killed | *A. baumannii* LAC-4 cells (5 × 10^7 CFU) | - | IN | WT, Igh-Jtm1Dhu, and Fcer1gtm1Rav BALB/c | LAC 4 | IN or IP | 5 × 10^5 CFU | IN challenge—100% | IP challenge—100% | [122] |
|              | Outer membrane vesicles or complexes | OMVs isolated from *A. baumannii* strain 19606 | Alum | SC | C57BL/6 | Ab112 | IP | 10^7 CFU | OMV vaccine w/Levofoxacin—85% | OMV vaccine only—0% | [77] |
|              |                  | OMVs isolated from *A. baumannii* strain 19606 | Alum | IM | C57BL/6 | ATCC 19606, Ab-154, Ab-113-16 | IP | 4.5 × 10^5 CFU | 19606 challenge—100% | Ab-154 challenge—90% | Ab-113-16—100% | [90] |
|              |                  | LPS-negative OMVs isolated from IB010 | Alum | IM | C57BL/6 | ATCC 19606 | IP | 1.8 × 10^6 CFU | 70% | [91] |
|              |                  | OMCs isolated from *A. baumannii* strain IB010 (ΔpxD) | Alum | IM | C57BL/6 | ATCC 19606 | IP | 1.6 × 10^6 CFU | 60% | [92] |
|              |                  | SulOMVs, nOMVs, or sOMVs isolated from strain 17978 | Alum | IM and IN | C57BL/6 | LAC 4 | IT | 2 × 10^7 CFU | IM—60–100% | IN—50–70% | [93] |
|              |                  | OMVs isolated from DH5α E.coli displaying *A. baumannii* Omp22 | Alum | SC | ICR | Ab1 | IP | 1.6 × 10^6 CFU | 100% | [123] |
|              |                  | *A. baumannii* IB010 | Alum | IM | C57BL/6 | ATCC 19606 | IP | 10^8 CFU | 100% | [124] |
|              |                  | OMVs isolated from *A. baumannii* strain Ab1 | Alum | IM | ICR | Ab1 | IN or IP | IN challenge—5 × 10^7 CFU | IP challenge—5.5 × 10^5 CFU | IN challenge—100% | IP challenge—75% | [125] |
| Immunization                        | Vaccine Platform                      | Antigens                              | Adjuvant(s) | Route | Mouse Strain | Strain          | Route | Dose     | Survival | Ref         |
|------------------------------------|---------------------------------------|---------------------------------------|-------------|-------|--------------|-----------------|-------|----------|----------|-------------|
| **DNA-based vaccine**              | DNA encoding *A. baumannii* OmpA gene | Alum                                  | IM          | BALB/c | MDR clinical | *A. baumannii* | IN    | $10^8$ CFU | 60%      | [94]        |
|                                   | DNA encoding genes for *A. baumannii* OmpA and Pal | CpG                                  | IM          | C57BL/6 | LAC 4        | IN or IT        | $3 \times 10^7$ CFU | IN challenge—80% | IT Challenge—50% | [95]        |
| rHis-Blp1(262–3362)                | Freund’s Adjuvant                     | IM                                    | BALB/c     | Ab1    | 10³ CFU      |                  |       |          | 60%      | [99]        |
| rHis-Bap                           | Freund’s Adjuvant                     | IM                                    | BALB/c     | Clinical isolate | IP     | $10^8$ CFU | 80%      | [100]       |
| rHis-Oma87                         | Freund’s Adjuvant                     | SC                                    | BALB/c     | 19606  | IP           | $2 \times 10^6$ CFU | 100% |          | [101]    |
| rHis-OprF_{26(5–200)}              | BCG and Alum                          | SC                                    | Swiss Albino | 9027  | IP           | $3.2 \times 10^9$ CFU | 50%  |          | [102]    |
| rHis-Omp22                         | Alum                                  | SC                                    | ICR         | 17978  | IP           | $1.6 \times 10^6$ CFU | 100% |          | [103]    |
| rHis-OmpA                          | Alum                                  | SC                                    | Retired breeder or juvenile BALB/c | HUMC1 | IV          | $2 \times 10^9$ CFU | Retired breeder—50% | Juvenile—45% | [104]     |
| rHis-OmpA                          | Cholera toxin                         | IN                                    | BALB/c     | 19606  | IP           | $5 \times 10^6$ CFU | 50%  |          | [105]    |
| rHis-PKF with anti-*A. baumannii* OmpA antibodies | Alum                                  | IP                                    | C57BL/6     | 19606  | IP           | $10^8$ CFU      | 85.71% |          | [107]    |
| rHis-FiiF                          | Freund’s Incomplete Adjuvant          | SC                                    | BALB/c     | 19606  | IT           | $10^8$ CFU      | 50%  |          | [108]    |
| rHis-BamA                          | Alum                                  | SC                                    | BALB/c     | 19606  | IN           | $10^8$ CFU      | 70%  |          | [113]    |
| rHis-NucAb                         | Freund’s complete adjuvant            | IP                                    | BALB/c     | 19606  | IT           | $10^8$ CFU      | 20%  |          | [114]    |
### Table 1. Cont.

| Immunization | Antigens | Adjuvant(s) | Route | Mouse Strain | Strain | Route | Dose | Survival | Ref |
|---------------|----------|-------------|-------|--------------|--------|-------|------|----------|-----|
| rHis-SmpA/PLD | rHis-CsuA/B and rHis-FimA | Freund’s Complete Adjuvant | SC | BALB/c | ST191 | IT | $10^8$ CFU | 66.7% | [115] |
| rHis-ZnuD (loop 2, 5, 7, or 11) attached to TbpA scaffold | | Freund’s Complete Adjuvant | SC | BALB/c | 19606 | IP | $2 \times 10^8$ CFU | Csu—60% Fim—50% Csu—33.3% | [117] |
| rHyr1p-N (Candida albicans) | | | SC | BALB/c | HUMC1 | Aerosol | $5 \times 10^7$ CFU | 50% | [121] |
| rHis-OmpK/Omp22 | | MF59 | IT | BALB/c | 19606 | IT | $10^8$ CFU | 83.3% | [126] |
| rHis-OmpK/Omp22 | | Freund’s complete adjuvant | SC | BALB/c | Ab1 | IP | $2 \times 10^8$ CFU | 66.7% | [127] |
| rHis-OmpW | | | SC | ICR | Ab1 | IP | $10^6$ CFU | 100% | [128] |

BGs = Bacterial ghost. SC = subcutaneous. SCA = subcutaneous with adjuvant. IMA = intramuscular with adjuvant. IT = Intratracheal. IP = Intraperitoneal. IM = Intramuscular. IN = Intranasal. IV = Intravenous. Aerosol = Aerosolization.
3. Conclusions

*A. baumannii* will likely remain a difficult organism to treat clinically due to its remarkable ability to develop antimicrobial resistance. However, a growing number of studies suggest that an effective vaccine could be developed against this organism. Several of the vaccine studies summarized in this review utilized computer learning and prediction software, and vaccine success in these pre-clinical studies indicates that AI and computer modeling should help inform rationale vaccine design in the future. Going forward, it will be important to identify which protective antigens are most highly conserved among *A. baumannii* clinical isolates in order to formulate a broadly protective multivalent vaccine. While some monovalent subunit vaccines successfully protected mice challenged with various clinical strains of *A. baumannii*, it is highly likely that multiple antigens will be necessary for complete vaccine protection. Analysis of the *A. baumannii* vaccine studies discussed in this review reveal the most effective vaccines are multivalent in nature (composed of outer membrane vesicles, bacterial ghosts, or multi-subunit) and are often composed of antigens present on the outer membrane of the bacteria (OmpA, OmpW, OmpK, and Omp22) [73,91,103,122–128]. This observation suggests that a cocktail of conserved surface proteins could be the most effective vaccine against a majority of *A. baumannii* clinical strains and warrants further investigation. This is not particularly surprising given that there are many FDA approved multicomponent vaccines on the market today, including the Diphtheria, Tetanus, and Pertussis (DTaP) and Meningitis B (MenB) vaccines. Lessons from other opportunistic bacteria, such as *Streptococcus pneumoniae*, highlight the importance of antigen choice to avoid the development of vaccine escape strains. In addition, the target population will influence the type of vaccine that is required as demonstrated by capsular polysaccharide-based vaccines for the elderly versus conjugate vaccines for children to prevent infection with pneumococcus. In this regard, it is important to determine which target populations require an *A. baumannii* vaccine. Although nosocomial infections with *A. baumannii* are worrisome, it is difficult to predict whether an individual will become hospitalized and require such a vaccine. Vaccination of healthcare workers could potentially limit the abundance and/or spread of *A. baumannii* in the hospital setting, but this would require a vaccine that eliminates bacterial colonization and carriage and may be difficult to accomplish. In the short term, populations that are most at risk include members of the armed forces. A vaccine designed to immunize military personnel must display an excellent safety profile, with minimal to no reactogenicity, in order to preserve military readiness. In the long term, the antimicrobial resistance crisis may dictate that all individuals require vaccination against *A. baumannii*, particularly if *A. baumannii* develops complete drug-resistance and becomes untreatable.

Author Contributions: Writing—original draft preparation, P.S.G. and A.A.W., writing—review and editing, L.A.M., funding acquisition, L.A.M. All authors have read and agree to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fernando, D.M.; Khan, I.U.H.; Patidar, R.; Lapen, D.R.; Talbot, G.; Topp, E.; Kumar, A. Isolation and Characterization of *Acinetobacter baumannii* Recovered from Campylobacter Selective Medium. *Front. Microbiol.* 2016, 7, 1871. [CrossRef]

2. Harding, C.M.; Hennon, S.W.; Feldman, M.F. Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nat. Rev. Microbiol.* 2018, 16, 91–102. [CrossRef] [PubMed]

3. Fitzpatrick, M.A.; Ozer, E.A.; Hauser, A.R. Utility of Whole-Genome Sequencing in Characterizing *Acinetobacter* Epidemiology and Analyzing Hospital Outbreaks. *J. Clin. Microbiol.* 2016, 54, 593–612. [CrossRef] [PubMed]
4. Sheppard, F.R.; Keiser, P.; Craft, D.W.; Gage, F.; Robson, M.; Brown, T.S.; Petersen, K.; Sincock, S.; Kasper, M.; Hawksworth, J.; et al. The majority of US combat casualty soft-tissue wounds are not infected or colonized upon arrival or during treatment at a continental US military medical facility. *Am. J. Surg.* **2010**, *200*, 489–495. [CrossRef] [PubMed]
5. Centers for Disease Control and Prevention (CDC). *Acinetobacter baumannii* infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. *MMWR Morb. Mortal. Wkly. Rep.* **2004**, *53*, 1063–1066.
6. Scott, P.; Deye, G.; Srinivasan, A.; Murray, C.; Moran, K.; Hulten, E.; Fishbain, J.; Craft, D.; Riddell, S.; Lindler, L.; et al. An outbreak of multidrug-resistant *Acinetobacter baumannii-calcoaceticus* complex infection in the US military health care system associated with military operations in Iraq. *Clin. Infect. Dis.* **2007**, *45*, 1577–1584. [CrossRef]
7. Lindberg, R.B.; Wetzler, T.F.; Marshall, J.D.; Newton, A.; Strawitz, J.G.; Howard, J.M. The bacterial flora of battle wounds at the time of primary debridement; a study of the Korean battle casualty. *Ann. Surg.* **1955**, *141*, 369–374. [CrossRef]
8. Murray, C.K.; Yun, H.C.; Griffith, M.E.; Hospenthal, D.R.; Tong, M.J. *Acinetobacter* infection: What was the true impact during the Vietnam conflict? *Clin. Infect. Dis.* **2006**, *43*, 383–384. [CrossRef]
9. Hawley, J.S.; Murray, C.K.; Griffith, M.E.; McElmeel, M.L.; Fulcher, L.C.; Hospenthal, D.R.; Jorgensen, J.H. Susceptibility of *Acinetobacter* strains isolated from deployed U.S. military personnel. *Antimicrob. Agents Chemother.* **2007**, *51*, 376–378. [CrossRef]
10. Towner, K.J. *Acinetobacter*: An old friend, but a new enemy. *J. Hosp. Infect.* **2009**, *73*, 355–363. [CrossRef]
11. Morris, F.C.; Dexter, C.; Kostoulas, X.; Uddin, M.I.; Peleg, A.Y. The Mechanisms of Disease Caused by *Acinetobacter baumannii*. *Front. Microbiol.* **2019**, *10*, 1601. [CrossRef] [PubMed]
12. Chung, D.R.; Song, J.-H.; Kim, S.H.; Thamlikitkul, V.; Huang, S.-G.; Wang, H.; So, T.M.; Yasin, R.M.D.; Hsueh, P.-R.; Carlos, C.C.; et al. High Prevalence of Multidrug-Resistant Nonfermenters in Hospital-acquired Pneumonia in Asia. *Am. J. Respir. Crit. Care Med.* **2011**, *184*, 1409–1417. [CrossRef] [PubMed]
13. Dananché, C.; Vanhems, P.; Machut, A.; Aupée, M.; Bervas, C.; L'Héritéau, F.; Lepape, A.; Lucet, J.-C.; Stoeckel, V.; Timsit, J.-F.; et al. Trends of Incidence and Risk Factors of Ventilator-Associated Pneumonia in Elderly Patients Admitted to French ICUs between 2007 and 2014. *Crit. Care Med.* **2018**, *46*, 869–877. [CrossRef] [PubMed]
14. Tabah, A.; Koulenti, D.; Laupland, K.; Misset, B.; Valles, J.; Bruzzi de Carvalho, F.; Paiva, J.A.; Çakar, N.; Ma, X.; Eggimann, P.; et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: The EUROBACT International Cohort Study. *Intensive Care Med.* **2012**, *38*, 1930–1945. [CrossRef]
15. Garnacho-Montero, J.; Timsit, J.-F. Managing *Acinetobacter baumannii* infections. *Curr. Opin. Infect. Dis.* **2019**, *32*, 69–76. [CrossRef]
16. Ayoub Moubareck, C.; Hammoudi Halat, D. Insights into *Acinetobacter baumannii*: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. *Antibiotics* **2020**, *9*, 119. [CrossRef]
17. Griffith, M.E.; Lazarus, D.R.; Mann, P.B.; Boger, J.A.; Hospenthal, D.R.; Murray, C.K. *Acinetobacter* skin carriage among US army soldiers deployed in Iraq. * Infect. Control Hosp. Epidemiol.* **2007**, *28*, 720–722. [CrossRef]
18. Hujer, K.M.; Hujer, A.M.; Hulten, E.A.; Bajaksouzian, S.; Adams, J.M.; Donskey, C.J.; Ecker, D.J.; Massire, C.; Eshoo, M.W.; Sampath, R.; et al. Analysis of antibiotic resistance genes in multidrug-resistant *Acinetobacter* sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. *Antimicrob. Agents Chemother.* **2006**, *50*, 4114–4123. [CrossRef]
19. Mohd Sazlly Lim, S.; Zainal Abidin, A.; Liew, S.M.; Roberts, J.A.; Sime, F.B. The global prevalence of multidrug-resistance among *Acinetobacter baumannii* causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. *J. Infect.* **2019**, *79*, 593–600. [CrossRef]
20. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet* **2020**, *395*, 507–513. [CrossRef]
21. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin. Infect. Dis.* [2020], ciaa530. [CrossRef] [PubMed]

22. Lai, C.-C.; Wang, C.-Y.; Hsueh, P.-R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? *J. Microbiol. Immunol. Infect.* [2020], 53, 505–512. [CrossRef] [PubMed]

23. Yu, N.; Li, W.; Kang, Q.; Xiong, Z.; Wang, S.; Lin, X.; Liu, Y.; Xiao, J.; Liu, H.; Deng, D.; et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study. *Lancet Infect. Dis.* [2020], 20, 559–564. [CrossRef]

24. Wang, Z.; Yang, B.; Li, Q.; Wen, L.; Zhang, R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin. Infect. Dis.* [2020], 71, 769–777. [CrossRef] [PubMed]

25. Zhu, X.; Ge, Y.; Wu, T.; Zhao, K.; Chen, Y.; Wu, B.; Zhu, F.; Zhu, B.; Cui, L. Co-infection with respiratory pathogens among COVID-2019 cases. *Virus Res.* [2020], 285, 198005. [CrossRef]

26. Lescure, F.-X.; Bouadma, L.; Nguyen, D.; Parisey, M.; Wicky, P.-H.; Behillil, S.; Gaymard, A.; Bouscambert-Duchamp, M.; Donati, F.; Le Hingrat, Q.; et al. Clinical and virological data of the first cases of COVID-19 in Europe: A case series. *Lancet Infect. Dis.* [2020], 20, 697–706. [CrossRef]

27. Fan, J.; Li, X.; Gao, Y.; Zhou, J.; Wang, S.; Huang, B.; Wu, J.; Cao, Q.; Chen, Y.; Wang, Z.; et al. The lung tissue microbiota features of 20 deceased patients with COVID-19. *J. Infect.* [2020], 81, e64–e67. [CrossRef]

28. Lima, W.G.; Brito, J.C.M.; da Cruz Nizer, W.S. Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant *Acinetobacter baumannii* in patients with COVID-19: Two problems, one solution? *Med. Hypotheses* [2020], 144, 110139. [CrossRef]

29. Zilberberg, M.D.; Nathanson, B.H.; Sulham, K.; Fan, W.; Shorr, A.F. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in *Acinetobacter baumannii* pneumonia and sepsis. *Crit. Care* [2016], 20, 221. [CrossRef]

30. Zilberberg, M.D.; Nathanson, B.H.; Sulham, K.; Fan, W.; Shorr, A.F. Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset *Acinetobacter baumannii* pneumonia or sepsis. *Crit. Care* [2017], 21, 130. [CrossRef]

31. Zurawski, D.V.; Banerjee, J.; Alamneh, Y.A.; Shearer, J.P.; Demons, S.T. Skin and Soft Tissue Models for *Acinetobacter baumannii* Infection. *Methods Mol. Biol.* [2019], 1946, 271–287. [CrossRef] [PubMed]

32. Tiwari, V.; Meena, K.; Tiwari, M. Differential anti-microbial secondary metabolites in different ES KA PE pathogens explain their adaptation in the hospital setup. *Infect. Genet. Evol.* [2018], 66, 57–65. [CrossRef] [PubMed]

33. Zurawski, D.V.; Black, C.C.; Alamneh, Y.A.; Biggemann, L.; Banerjee, J.; Thompson, M.G.; Wise, M.C.; Honnold, C.L.; Kim, R.K.; Paranavitana, C.; et al. A Porcine Wound Model of *Acinetobacter baumannii* Infection. *Adv. Wound Care* [2019], 8, 14–27. [CrossRef] [PubMed]

34. Almasaudi, S.B. *Acinetobacter* spp. as nosocomial pathogens: Epidemiology and resistance features. *Saudi J. Biol. Sci.* [2018], 25, 586–596. [CrossRef]

35. Karaiskos, I.; Galani, L.; Baziaka, F.; Katsouda, E.; Ioannidis, I.; Andreou, A.; Paskalis, H.; Giamarellou, H. Successful treatment of extensively drug-resistant *Acinetobacter baumannii* ventriculitis and meningitis with intraventricular colistin after application of a loading dose: A case series. *Int. J. Antimicrob. Agents* [2013], 41, 480–483. [CrossRef]

36. Jiménez-Mejías, M.E.; Pachón, J.; Becerril, B.; Palomino-Nicás, J.; Rodriguez-Cobacho, A.; Revuelta, M. Treatment of multidrug-resistant *Acinetobacter baumannii* meningitis with ampicillin/sulbactam. *Clin. Infect. Dis.* [1997], 24, 932–935. [CrossRef]

37. Cascio, A.; Conti, A.; Sinardi, L.; Iaria, C.; Angileri, F.F.; Stassi, G.; David, T.; Versaci, A.; Iaria, M.; David, A. Post-neurosurgical multidrug-resistant *Acinetobacter baumannii* meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. *Int. J. Infect. Dis.* [2010], 14, e572–e579. [CrossRef]

38. Karakuzu, Z.; Iscimen, R.; Akalin, H.; Kelebek Girgin, N.; Kahveci, F.; Siritas, M. Prognostic Risk Factors in Ventilator-Associated Pneumonia. *Med. Sci. Monit.* [2018], 24, 1321–1328. [CrossRef]

39. Spelberg, B.; Bonomo, R.A. “Airborne Assault”: A New Dimension in *Acinetobacter baumannii* Transmission. *Crit. Care Med.* [2013], 41, 2042–2044. [CrossRef]
40. Mousa, M.; Schwartz, D.; Carmeli, Y.; Nutman, A. Droplet aerosol dissemination of carbapenem-resistant *Acinetobacter baumannii* surrounding ventilated patients. *Infect. Control Hosp. Epidemiol.* 2019, 40, 365–367. [CrossRef]

41. Di Venanzio, G.; Flores-Mireles, A.L.; Calix, J.J.; Haurat, M.F.; Scott, N.E.; Palmer, L.D.; Potter, R.F.; Hibbing, M.E.; Friedman, L.; Wang, B.; et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic *Acinetobacter baumannii* chromosomal genes. *Nat. Commun.* 2019, 10, 2763. [CrossRef] [PubMed]

42. Dijkshoorn, L.; van Aken, E.; Shunburne, L.; van der Reijden, T.J.K.; Bernards, A.T.; Nemec, A.; Towner, K.J. Prevalence of *Acinetobacter baumannii* and other *Acinetobacter* spp. in faecal samples from non-hospitalised individuals. *Clin. Microbiol. Infect.* 2005, 11, 329–332. [CrossRef] [PubMed]

43. Guerrero, D.M.; Perez, F.; Conger, N.G.; Solomkin, J.S.; Adams, M.D.; Rather, P.N.; Bonomo, R.A. *Acinetobacter baumannii*-Associated Skin and Soft Tissue Infections: Recognizing a Broadening Spectrum of Disease. *Surg. Infect.* 2010, 11, 49–57. [CrossRef] [PubMed]

44. Thom, K.A.; Rock, C.; Jackson, S.S.; Johnson, J.K.; Srinivasan, A.; Magder, L.S.; Roghmann, M.-C.; Selasi, G.N.; Nicholas, A.; Jeon, H.; Na, S.H.; Kwon, H.I.; Kim, Y.J.; Heo, S.T.; Oh, M.H.; Lee, J.C. Di... [CrossRef] [PubMed]

45. Chiang, S.-R.; Jung, F.; Tang, H.-J.; Chen, C.-H.; Chen, C.-C.; Chou, H.-Y.; Chuang, Y.-C. Desiccation and ethanol resistances of multidrug resistant *Acinetobacter baumannii* embedded in biofilm: The favorable antiseptic efficacy of combination chlorhexidine gluconate and ethanol. *J. Microbiol. Immunol. Infect.* 2018, 51, 770–777. [CrossRef] [PubMed]

46. Kasimova, A.A.; Sheinder, M.M.; Arbatsky, N.P.; Popova, A.V.; Shashkov, A.S.; Miroshnikov, K.A.; Balaji, V.; Biswas, I.; Knirel, Y.A. Structure and Gene Cluster of the K93 Capsular Polysaccharide of *Acinetobacter baumannii* B11911 Containing 5-N-Acetyl-7-N-[(R)-3-hydroxybutanoyl]pseudaminic Acid. *Biochemistry (Moscow)* 2017, 82, 483–489. [CrossRef] [PubMed]

47. Kenyon, J.J.; Speciale, I.; Hall, R.M.; De Castro, C. Structure of repeating unit of the capsular polysaccharide from *Acinetobacter baumannii* D78 and assignment of the K4 gene cluster. *Carbohydr. Res.* 2016, 434, 12–17. [CrossRef] [PubMed]
58. Aranda, J.; Bardina, C.; Beceiro, A.; Rumbo, S.; Cabral, M.P.; Barbé, J.; Bou, G. *Acinetobacter baumannii* RecA protein in repair of DNA damage, antimicrobial resistance, general stress response, and virulence. *J. Bacteriol.* 2011, 193, 3740–3747. [CrossRef]

59. Centers for Disease Control and Prevention (U.S.). *Antibiotic Resistance Threats in the United States, 2019*; Centers for Disease Control and Prevention (U.S.): Atlanta, GA, USA, 2019.

60. Holt, K.; Kenyon, J.J.; Hamidian, M.; Schultz, M.B.; Pickard, D.J.; Dougan, G.; Hall, R. Five decades of genome evolution in the globally distributed, extensively antibiotic-resistant *Acinetobacter baumannii* global clone 1. *Microb. Genom.* 2016, 2, e000052. [CrossRef]

61. Schultz, M.B.; Pham Thanh, D.; Tran Do Hoan, N.; Wick, R.R.; Ingle, D.J.; Hawkey, J.; Edwards, D.J.; Kenyon, J.J.; Phu Huong Lan, N.; Campbell, J.I.; et al. Repeated local emergence of carbapenem-resistant *Acinetobacter baumannii* in a single hospital ward. *Microb. Genom.* 2016, 2, e000050. [CrossRef]

62. Wright, M.S.; Haft, D.H.; Harkins, D.M.; Perez, F.; Hujer, K.M.; Bajaksouzian, S.; Benard, M.F.; Jacobs, M.R.; Isler, B.; Doi, Y.; Bonomo, R.A.; Paterson, D.L. New Treatment Options against Carbapenem-Resistant *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2013, 57, 661–674. [CrossRef] [PubMed]

63. Kenyon, J.J.; Hall, R.M. Variation in the complex carbohydrate biosynthesis loci of *Acinetobacter baumannii* genomes. *PLoS ONE* 2013, 8, e62160. [CrossRef] [PubMed]

64. Damier-Piolle, L.; Magnet, S.; Brémont, S.; Lambert, T.; Courvalin, P. AdelJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2008, 52, 557–562. [CrossRef]

65. Coyne, S.; Courvalin, P.; Périchon, B. Efflux-Mediated Antibiotic Resistance in *Acinetobacter* spp. *Antimicrob. Agents Chemother.* 2011, 55, 947–953. [CrossRef]

66. Sun, J.; Zhang, H.; Liu, Y.-H.; Feng, Y. Towards Understanding MCR-like Colistin Resistance. *Trends Microbiol.* 2018, 26, 794–808. [CrossRef]

67. Årdal, C.; Balasegaram, M.; Laxminarayan, R.; McAdams, D.; Outterson, K.; Rex, J.H.; Sumpradit, N. Antibiotic development—Economic, regulatory and societal challenges. *Nat. Rev. Microbiol.* 2020, 18, 267–274. [CrossRef]

68. Isler, B.; Doi, Y.; Bonomo, R.A.; Paterson, D.L. New Treatment Options against Carbapenem-Resistant *Acinetobacter baumannii* Infections. *Antimicrob. Agents Chemother.* 2018, 63, e01110-18. [CrossRef]

69. Tabrizi, C.A.; Walcher, P.; Mayr, U.B.; Stiedl, T.; Binder, M.; McGrath, J.; Lubitz, W. Bacterial ghosts – biological particles as delivery systems for antigens, nucleic acids and drugs. *Curr. Opin. Biotechnol.* 2004, 15, 530–537. [CrossRef] [PubMed]

70. Cabral, M.P.; Garcia, P.; Beeceiro, A.; Rumbo, C.; Perez, A.; Moscoso, M.; Bou, G. Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. *Nat. Commun.* 2017, 8, 15480. [CrossRef] [PubMed]

71. Ainsworth, S.; Ketter, P.M.; Yu, J.-J.; Grimm, R.C.; May, H.C.; Cap, A.P.; Chambers, J.P.; Guentzel, M.N.; Arulananandam, B.P. Vaccination with a live attenuated *Acinetobacter baumannii* deficient in thioredoxin provides protection against systemic *Acinetobacter* infection. *Vaccine* 2017, 35, 3387–3394. [CrossRef] [PubMed]

72. Zeller, T.; Klug, G. Thioredoxins in bacteria: Functions in oxidative stress response and regulation of thioredoxin genes. *Naturwissenschaften* 2006, 93, 259–266. [CrossRef]

73. Sheweita, S.A.; Batah, A.M.; Ghazy, A.A.; Hussein, A.; Amara, A.A. A new strain of *Acinetobacter baumannii* and characterization of its ghost as a candidate vaccine. *J. Infect. Public Health* 2012, 5, 831–842. [CrossRef] [PubMed]

74. Huang, W.; Zhang, Q.; Li, W.; Chen, Y.; Shu, C.; Li, Q.; Zhou, J.; Ye, C.; Bai, H.; Sun, W.; et al. Anti-outer Membrane Vesicle Antibodies Increase Antibiotic Sensitivity of Pan-Drug-Resistant *Acinetobacter baumannii*. *Front. Microbiol.* 2019, 10, 1379. [CrossRef] [PubMed]

75. Mancini, F.; Rossi, O.; Necchi, F.; Micoli, F. OMV Vaccines and the Role of TLR Agonists in Immune Response. *IJMS* 2020, 21, 4416. [CrossRef]
97. Wang, H.; Liang, K.; Kong, Q.; Liu, Q. Immunization with outer membrane vesicles of avian pathogenic *Escherichia coli* O78 induces protective immunity in chickens. *Vet. Microbiol.* 2019, 236, 108367. [CrossRef] [PubMed]

98. Asensio, C.J.A.; Gaillard, M.E.; Moreno, G.; Bottero, D.; Zurita, E.; Rumbo, M.; van der Ley, P.; van der Ark, A.; Hozbor, D. Outer membrane vesicles obtained from *Burkholderia pseudomallei* Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. *Vaccine* 2011, 29, 1649–1656. [CrossRef] [PubMed]

99. Nieves, W.; Petersen, H.; Judy, B.M.; Blumentritt, C.A.; Russell-Lodrigue, K.; Roy, C.J.; Torres, A.G.; Morici, L.A. A *Burkholderia pseudomallei* Outer Membrane Vesicle Vaccine Provides Protection against Lethal Sepsis. *Clin. Vaccine Immunol.* 2014, 21, 747–754. [CrossRef] [PubMed]

100. Baker, S.; Davitt, C.; Motyka, N.; Kikendall, N.; Russell-Lodrigue, K.; Roy, C.; Morici, L. A *Burkholderia pseudomallei* Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glands in Mice and Non-Human Primates. *Vaccines* 2017, 5, 49. [CrossRef]

101. Nieves, W.; Asakrah, S.; Qazi, O.; Brown, K.A.; Kurtz, J.; AuCoin, D.P.; McLachlan, J.B.; Roy, C.J.; Morici, L.A. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary *Burkholderia pseudomallei* infection. *Vaccine* 2011, 29, 8381–8389. [CrossRef]

102. Petersen, H.; Nieves, W.; Russell-Lodrigue, K.; Roy, C.J.; Morici, L.A. Evaluation of a *Burkholderia Pseudomallei* Outer Membrane Vesicle Vaccine in Nonhuman Primates. *Procedia Vaccinol.* 2014, 8, 38–42. [CrossRef]

103. Van de Waterbeemd, B.; Streffland, M.; van der Ley, P.; Zomer, B.; van Dijken, H.; Martens, D.; Wijffels, R.; van der Pol, L. Improved OMV vaccine against *Neisseria meningitidis* using genetically engineered strains and a detergent-free purification process. *Vaccine* 2010, 28, 4810–4816. [CrossRef]

104. Oster, P.; Lennon, D.; Ohallahah, J.; Mulholland, K.; Reid, S.; Martin, D. MeNZB?: A safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strain. *Vaccine* 2005, 23, 2191–2196. [CrossRef]

105. McConnell, M.J.; Rumbo, C.; Bou, G.; Pachón, J. Outer membrane vesicles as an acellular vaccine against *Acinetobacter baumannii*. *Vaccine* 2011, 29, 5705–5710. [CrossRef] [PubMed]

106. Pulido, M.R.; García-Quintanilla, M.; Pachón, J.; McConnell, M.J. A lipopolysaccharide-free outer membrane vesicle vaccine protects against *Acinetobacter baumannii* infection. *Vaccine* 2020, 38, 719–724. [CrossRef]

107. Pulido, M.R.; García-Quintanilla, M.; Pachón, J.; McConnell, M.J. Immunization with lipopolysaccharide-free outer membrane complexes protects against *Acinetobacter baumannii* infection. *Vaccine* 2018, 36, 4153–4156. [CrossRef] [PubMed]

108. Li, S.; Chen, D.-Q.; Ji, L.; Sun, S.; Jin, Z.; Jin, Z.-L.; Sun, H.-W.; Zeng, H.; Zhang, W.-J.; Lu, D.-S.; et al. Development of Different Methods for Preparing *Acinetobacter baumannii* Outer Membrane Vesicles Vaccine: Impact of Preparation Method on Protective Efficacy. *Front. Immunol.* 2020, 11, 1069. [CrossRef] [PubMed]

109. Ansari, H.; Tahmasebi-Birgani, M.; Bijanazadeh, M.; Doosti, A.; Kargar, M. Study of the immunogenicity of outer membrane protein A (ompA) gene from *Acinetobacter baumannii* as DNA vaccine candidate in vivo. *Iran. J. Basic Med. Sci.* 2019, 22, 669–675. [CrossRef] [PubMed]

110. Lei, L.; Yang, F.; Zou, J.; Jing, H.; Zhang, J.; Xu, W.; Zou, Q.; Zhang, J.; Wang, X. DNA vaccine encoding OmpA and Pal from *Acinetobacter baumannii* efficiently protects mice against pulmonary infection. *Mol. Biol. Rep.* 2019, 46, 5397–5408. [CrossRef]

111. Wang-Lin, S.X.; Olson, R.; Beanan, J.M.; MacDonald, U.; Balthasar, J.P.; Russo, T.A. The Capsular polysaccharide of *Acinetobacter baumannii* Is an Obstacle for Therapeutic Passive Immunization Strategies. *Infect. Immun.* 2017, 85, e00591-17. [CrossRef]
97. Russo, T.A.; Beanan, J.M.; Olson, R.; MacDonald, U.; Cox, A.D.; St. Michael, F.; Vinogradov, E.V.; Spellberg, B.; Luke-Marshall, N.R.; Campagnari, A.A. The K1 Capsular polysaccharide from Acinetobacter baumannii is a Potential Therapeutic Target via Passive Immunization. Infect. Immun. 2013, 81, 915–922. [CrossRef]

98. De Gregorio, E.; Del Franco, M.; Martinucci, M.; Rossetto, E.; Zarrilli, R.; Di Nocera, P.P. Biofilm-associated proteins: News from Acinetobacter. BMC Genom. 2015, 16, 933. [CrossRef]

99. Skerniškytė, J.; Karazijaitė, E.; Deschamps, J.; Krasauskas, R.; Armalytė, J.; Briandet, R.; Sužiedėlieniė, E. Blp1 protein shows virulence-associated features and elicits protective immunity against Acinetobacter baumannii infection. BMC Microbiol. 2019, 19, 259. [CrossRef]

100. Fattahian, Y.; Rasooli, I.; Mousavi Gargari, S.L.; Rahbar, M.R.; Darvish Alipour Astaneh, S.; Amani, J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb. Pathog. 2011, 51, 402–406. [CrossRef]

101. Rasooli, I.; Abdolhamidii, R.; Jahangiri, A.; Darvish Alipour Astaneh, S. Outer Membrane Protein, Oma87 Prevents Acinetobacter baumannii Infection. Int. J. Pept. Res. Ther. 2020. [CrossRef]

102. Bahey-El-Din, M.; Mohamed, S.A.; Sheweita, S.A.; Haroun, M.; Zaghloul, T.I. Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii. Int. J. Med. Microbiol. 2020, 310, 151415. [CrossRef] [PubMed]

103. Huang, W.; Yao, Y.; Wang, S.; Xia, Y.; Yang, X.; Long, Q.; Sun, W.; Liu, C.; Li, Y.; Chu, X.; et al. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci. Rep. 2016, 6, 20724. [CrossRef] [PubMed]

104. Luo, G.; Lin, L.; Ibrahim, A.S.; Baquir, B.; Pantapalangkoor, P.; Bonomo, R.A.; Doi, Y.; Adams, M.D.; Russo, T.A.; Spellberg, B. Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection. PLoS ONE 2012, 7, e29446. [CrossRef] [PubMed]

105. Badmasti, F.; Ajardy, S.; Bouzari, S.; Fooladi, A.A.I.; Shahcheraghi, F.; Siadat, S.D. Immunological evaluation of OMV(PagL)+Bap(1-487aa) and AbOmpA(8-346aa)+Bap(1-487aa) as vaccine candidates against Acinetobacter baumannii sepsis infection. Mol. Immunol. 2015, 67, 552–558. [CrossRef] [PubMed]

106. Zhang, X.; Yang, T.; Cao, J.; Sun, J.; Dai, W.; Zhang, L. Mucosal immunization with purified OmpA elicits protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb. Pathog. 2016, 96, 20–25. [CrossRef]

107. Bolourchi, N.; Shahcheraghi, F.; Shirazi, A.S.; Janani, A.; Bahrami, F.; Badmasti, F. Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of Acinetobacter baumannii. Microb. Pathog. 2019, 131, 9–14. [CrossRef]

108. Singh, R.; Garg, N.; Shukla, G.; Capalash, N.; Sharma, P. Immunoprotective Efficacy of Acinetobacter baumannii Outer Membrane Protein, FilF, Predicted In silico as a Potential Vaccine Candidate. Front. Microbiol. 2016, 7, 158. [CrossRef]

109. Arora, S.; Thavaselvam, D.; Kumar, A.; Prakash, A.; Barua, A.; Sathyaseelan, K. Cloning, expression and purification of outer membrane protein (OmpA) of Burkholderia pseudomallei and evaluation of its potential for serodiagnosis of melioidosis. Diagn. Microbiol. Infect. Dis. 2015, 81, 79–84. [CrossRef]

110. Weidensdorfer, M.; Chae, J.I.; Makobe, C.; Stahl, J.; Averhoff, B.; Müller, V.; Schürmann, C.; Brandes, R.P.; Wilharm, G.; Ballhorn, W.; et al. Analysis of Endothelial Adherence of Bartonella henselae and Acinetobacter baumannii Using a Dynamic Human Ex Vivo Infection Model. Infect. Immun. 2016, 84, 711–722. [CrossRef]

111. Bentancor, L.V.; Camacho-Peiro, A.; Bozkurt-Guzel, C.; Pier, G.B.; Maira-Litran, T. Identification of Ata, a Multifunctional Trimeric Autotransporter of Acinetobacter baumannii. J. Bacteriol. 2012, 194, 3950–3960. [CrossRef]

112. Bentancor, L.V.; Routray, A.; Bozkurt-Guzel, C.; Camacho-Peiro, A.; Pier, G.B.; Maira-Litran, T. Evaluation of the Trimeric Autotransporter Ata as a Vaccine Candidate against Acinetobacter baumannii Infections. Infect. Immun. 2012, 80, 3381–3388. [CrossRef] [PubMed]

113. Singh, R.; Capalash, N.; Sharma, P. Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii. Sci. Rep. 2017, 7, 12411. [CrossRef] [PubMed]

114. Garg, N.; Singh, R.; Shukla, G.; Capalash, N.; Sharma, P. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb. Int. J. Med. Microbiol. 2016, 306, 1–9. [CrossRef] [PubMed]
115. Li, H.; Tan, H.; Hu, Y.; Pan, P.; Su, X.; Hu, C. Small protein A and phospholipase D immunization serves a protective role in a mouse pneumonia model of *Acinetobacter baumannii* infection. *Mol. Med. Rep.* 2017, 16, 1071–1078. [CrossRef]

116. Ronish, L.A.; Lilleyhoj, E.; Fields, J.K.; Sundberg, E.J.; Piepenbrink, K.H. The structure of PilA from *Acinetobacter baumannii* AB5075 suggests a mechanism for functional specialization in Acinetobacter type IV pili. *J. Biol. Chem.* 2019, 294, 218–230. [CrossRef]

117. Ramezanalizadeh, F.; Owlia, P.; Rasooli, I. Type I pili, CsuA/B and FimA induce a protective immune response against *Acinetobacter baumannii*. *Vaccine* 2020, 38, 5436–5446. [CrossRef]

118. Qamsari, M.M.; Rasooli, I.; Chaudhuri, S.; Astaneh, S.D.A.; Schryvers, A.B. Hybrid Antigens Expressing Surface Loops of ZnuD from *Acinetobacter baumannii* Is Capable of Inducing Protection against Infection. *Front. Immunol.* 2020, 11, 158. [CrossRef]

119. Covian, C.; Fernández-Fierro, A.; Retamal-Díaz, A.; Díaz, F.E.; Vasquez, A.E.; Lay, M.K.; Riedel, C.A.; González, P.A.; Bueno, S.M.; Kalergis, A.M. BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. *Front. Immunol.* 2019, 10, 2806. [CrossRef]

120. Juárez-Rodríguez, M.D.; Yang, J.; Kader, R.; Alamuri, P.; Curtiss, R.; Clark-Curtiss, J.E. Live Attenuated Salmonella Vaccines Displaying Regulated Delayed Lysis and Delayed Antigen Synthesis To Confer Protection against *Mycobacterium tuberculosis*. *Infec. Immun.* 2012, 80, 815–831. [CrossRef]

121. Uppuluri, P.; Lin, L.; Alqarihi, A.; Luo, G.; Youssef, E.G.; Alkhazraji, S.; Yount, N.Y.; Ibrahim, B.A.; Bolaris, M.A.; Edwards, J.E.; et al. The Hyr1 protein from the fungus *Candida albicans* is a cross kingdom immunotherapeutic target for *Acinetobacter* bacterial infection. *PLoS Pathog.* 2018, 14, e1007056. [CrossRef]

122. KuoLee, R.; Harris, G.; Yan, H.; Xu, H.H.; Conlan, W.J.; Patel, G.B.; Chen, W. Intranasal immunization protects against *Acinetobacter baumannii*-associated pneumonia in mice. *Vaccine* 2015, 33, 260–267. [CrossRef] [PubMed]

123. Huang, W.; Wang, S.; Yao, Y.; Xia, Y.; Yang, X.; Li, K.; Sun, P.; Liu, C.; Sun, W.; Bai, H.; et al. Employing *Escherichia coli*-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against *Acinetobacter baumannii* infection. *Sci. Rep.* 2016, 6, 37242. [CrossRef] [PubMed]

124. García-Quintanilla, M.; Pulido, M.R.; Pachón, J.; McConnell, M.J. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of *Acinetobacter baumannii* infection. *PLoS ONE* 2014, 9, e114410. [CrossRef] [PubMed]

125. Huang, W.; Yao, Y.; Long, Q.; Yang, X.; Sun, W.; Liu, C.; Jin, X.; Li, Y.; Chu, X.; Chen, B.; et al. Immunization against multidrug-resistant *Acinetobacter baumannii* effectively protects mice in both pneumonia and sepsis models. *PLoS ONE* 2014, 9, e100727. [CrossRef] [PubMed]

126. Yang, A.-Q.; Yang, H.-Y.; Guo, S.-J.; Xie, Y.-E. MF59 adjuvant enhances the immunogenicity and protective immunity of the OmpK/Omp22 fusion protein from *Acinetobacter baumannii* through intratracheal inoculation in mice. *Scand J. Immunol.* 2019, 90, e12769. [CrossRef]

127. Guo, S.J.; Ren, S.; Xie, Y.E. Evaluation of the Protective Efficacy of a Fused OmpK/Omp22 Protein Vaccine Candidate against *Acinetobacter baumannii* Infection in Mice. *Biomed. Environ. Sci.* 2018, 31, 155–158. [CrossRef]

128. Huang, W.; Wang, S.; Yao, Y.; Xia, Y.; Yang, X.; Long, Q.; Sun, W.; Liu, C.; Li, Y.; Ma, Y. OmpW is a potential target for eliciting protective immunity against *Acinetobacter baumannii* infections. *Vaccine* 2015, 33, 4479–4485. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.